[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583752":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":48,"collaborators":19,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":19,"enrollmentInfo":60,"targetDuration":19,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ALZHEIMER PATIENTS and NON ALZHEIMER PATIENTS","EXPERIMENTAL","Recruitment of 75 patients with amyloid positive marker on cerebrospinal fluid and 75 patients with amyloid negative marker on cerebrospinal fluid and 75 healthy volonteers",[13],"Other: MMSE and blood draw",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"MMSE and blood draw","Each patient will be evaluated by Mini-Mental State Examination (MMSE) and will have a blood draw",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Aurélie MOUTON, MD,PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Justine Lemaire","CONTACT","33492034778","lemaire.j@chu-nice.fr",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"CHU de Nice","RECRUITING","Nice","PACA","06000","France","FR",{"type":40,"coordinates":41},"Point",[42,43],7.26608,43.70313,{"lat":43,"lon":42},[46,47],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":49,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100583752","mitochondrial-function-and-metabolomic-profile-in-alzheimers-disease-and-related-dementias-100583752",false,"NCT06880406","Mitochondrial Function and Metabolomic Profile in Alzheimer's Disease and Related Dementias","Early Alterations of Peripheral Mitochondrial Function and Metabolomic Profile in Patients With Alzheimer's Disease and Related Dementias","AMPAlz","Inclusion Criteria:\n\n* Neurocognitive disorder with spontaneous complaint or reported for at least 6 months\n* Diagnostic process according to current Haute Autorité de Santé (HAS) recommendations.\n* cerebrospinal fluid biomarker dosage done within the study center and agreement to bio-collection of residual cerebrospinal fluid\n* Patient having agreed to sign the informed consent\n* Patient affiliated or beneficiary of a social security scheme\n\nFor alzheimer group : diagnosis of Alzheimer's disease according to NIA-AA 2024 criteria (presence of a pathogenic amyloid process in the cerebrospinal fluid)\n\nFor non alzheimer group : diagnosis of mild or major neurocognitive disorder according to Manuel diagnostique et statistique des troubles mentaux edition 5 (DSM-V) criteria, not linked to Alzheimer's disease (absence of pathogenic amyloid process in the cerebrospinal fluid)\n\nFor healthy volonteers:\n\n* Adult patients\n* No history of neurological or psychiatric disorders\n* No complaints of memory problems or cognitive impairment\n* Mini-Mental State Examination (MMSE) score ≥ 27\u002F30\n* Clinical Dementia Rating - Sum of Boxes (CDR-SOB) equal to 0\n* Patient affiliated with or covered by a social security scheme\n\nExclusion Criteria:\n\n\\- Vulnerable people","ALL","18 Years",{"count":61,"type":62},250,"ESTIMATED","INTERVENTIONAL",[65],"NA","This project aims to study on one hand the early mitochondrial alterations, common or specific, occurring in peripheral cells of patients with Alzheimer's disease or related dementia and, on the other hand, identify the metabolomic biomarkers that may be at the origin of mitochondrial disturbances associated with the disease. This will be the first study combining functional analyses of mitochondria and exploratory metabolomic assessments in the same cohort at early stages of the disease.",[68],"Alzheimer Disease",[70,71,72],"Alzheimer","mitochondrial function","metabolomic","2026-06-16",{"date":75,"type":76},"2026-06-18","ACTUAL",{"date":78,"type":76},"2025-07-01",{"date":80,"type":62},"2029-04-01",{"name":5,"class":6},1]